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a pilot project to collect this data and make it available for evaluation and planning 
processes in a standardized language according to CAP (Catalog for ambulatory 
procedures). METHODS: The data will be transferred into a new database in two 
data streams to ensure data protection. Data about the patient containing sex, age 
and other characteristics will be sent in a pseudonomyzed way in one data stream. 
Another will contain data about the procedures according to CAP and information 
about contract physicians, outpatient clinics and ambulatories. RESULTS: The new 
database will offer information about what until now has been more or less a black 
spot. It will give information about procedures performed in the ambulatory and 
outpatient sector for all stakeholders participating in this pilot project. CONCLU-
SIONS: Data about outpatient clinics and ambulatories have not been made accessible 
in one database for all participating stakeholders in a standardized language until now. 
The initiated pilot project and the database created therewith offer an opportunity to 
cover this lack of information.
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BACKGROUND: Incremental cost-effectiveness ratios (ICERs) represent the cost per 
unit of effectiveness of switching to a more costly and more effective option. In report-
ing results for cost-effectiveness (CE) analyses, options that are strictly dominated are 
ruled out and no ICERs should be reported. Additionally, some options may be ruled 
out by extended dominance (i.e., there is a linear combination of two options that 
dominates an option not otherwise excluded by strict dominance). In order to plot 
the CE efﬁciency frontier both strictly and extendedly dominated options must be 
excluded. Calculating strict dominance (e.g., in Excel) is straightforward. However 
calculating extended dominance is more complex. METHODS: We present a method 
to exclude extendedly dominated options using an ICER matrix. To form an ICER 
matrix all options are rank ordered by cost. For a CE analysis with N options, the 
ICER matrix is an N x N-1 sized table, where the ﬁrst column represents the ICER 
from the least costly option to each more costly option, the second column represents 
the ICER from the second least costly option to each more costly option, etc.. Negative 
ICERs, representing strictly dominated options, are excluded from the table. Extended 
dominance is established by calculating whether the ICER for a non-strictly dominated 
option is greater than the ICER for at least one more costly option. If so, the option 
is rule out by extended dominance, otherwise not. We show how to perform the 
required calculations in Excel and how to graphically plot the CE efﬁciency frontier 
once all dominated and extendedly dominated options have been excluded. CONCLU-
SIONS: Strictly dominated and extendedly dominated options must be ruled out in 
order to plot the CE efﬁciency frontier. The ICER matrix is a systematic method to 
rule out strictly and extendedly dominated options.
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BACKGROUND: The cost-effectiveness acceptability curve (CEAC) graphically 
depicts the joint uncertainty in a probabilistic model by transforming the incremental 
cost-effectiveness ratio into a net-beneﬁt framework to represent the probability that 
a strategy is cost-effective over a range of willingness-to-pay (WTP) thresholds. By 
characterizing the joint distribution of costs and effects for all model parameters, the 
CEAC simpliﬁes the presentation of uncertainty compared to deterministic one-way 
and multi-way sensitivity analyses and allows decision makers to identify the preferred 
strategy based on their WTP threshold. However, in some instances presenting only 
the joint uncertainty may be a limitation of the CEAC. METHODS: We propose a 
method to graphically present the uncertainty contributed by a single parameter within 
a probabilistic model called the cost-effectiveness sensitivity curve (CESC). Like the 
CEAC, the y-axis of the CESC represents the probability that a strategy is cost-
effective. However, instead of WTP, the x-axis represents a speciﬁed range of values 
for a single model parameter. The CESC is generated by varying the chosen parameter 
over the speciﬁed range of values and calculating the net-beneﬁt at each value for each 
simulation based on the sampled values of the remaining model parameters without 
resampling (note: to effect the net-beneﬁt transformation the CESC is based on a single 
WTP threshold). Computationally, the CESC requires an additional series of calcula-
tions for each simulation corresponding to the desired number of points on the curve. 
The advantage of the CESC is that it probabilistically describes the effect of uncer-
tainty of a single model parameter on cost-effectiveness. This is particularly useful for 
ex-ante pricing decisions and for early phase go/no-go decisions based on an antici-
pated range of effectiveness. CONCLUSIONS: The CESC is a useful tool in speciﬁc 
decision making contexts for quantifying the contribution of a single model parameter 
to uncertainty within a probabilistic model.
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OBJECTIVES: The objective of this study was to examine whether the Over-the-
Counter Medication Label Evaluation Process Model (OTC-LEPM) or its modiﬁed 
version explained consumer’s purchase intention better. METHODS: Data collected 
during an experimental ﬁeld study was reanalyzed using structural equation modeling 
(SEM). Purchase intention with regard to three OTC medications for pain was evalu-
ated using simulated product package labels for Acetaminophen, Ibuprofen and 
Aspirin. The experiment was conducted with consumers in the process of selecting an 
OTC product at local pharmacy stores. Endogenous variables were product knowl-
edge, product evaluation, attitude-toward-product label and purchase intention. An 
additional endogenous variable ease of use was used in the modiﬁed OTC-LEPM. 
Demographics collected were analyzed using descriptive analysis in SPSS. AMOS v17 
was used to conduct SEM and test whether OTC-LEPM or modiﬁed OTC-LEPM was 
the better model to explain the variables that predict purchase intention. RESULTS: 
A total of 336 consumers participated in the study. A chi-square value using the SEM 
approach for OTC-LEPM was 6262.390. The SEM for the modiﬁed OTC-LEPM 
indicated that iteration limit was reached (55000). Alternative model approach pro-
duced 3 models with slightly better chi-square value. A new model was built by 
combining alternative model approach and McFadden’s Choice Process. This model 
produced an improved ﬁt, producing a chi-square value of 4697 (df = 902, p < 0.0001). 
This model validated that knowledge signiﬁcantly causes attitude towards product 
label which directly and indirectly via product evaluation causes purchase intention 
and these causal links were statistically signiﬁcant. It indicated that only one exoge-
nous variable age was statistically signiﬁcant. CONCLUSIONS: The modiﬁed OTC-
LEPM may not be the best model to analyze consumer’s OTC medication purchase 
intention. Further research is needed to evaluate variables that can improve the under-
standing of consumer’s purchase intention.
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ENHANCES EFFICIENCY OF PROBABILISTIC MODELS
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The inclusion of probabilistic components in health care models requires the imple-
mentation of random number sampling. Many microsimulation models use a single 
simple random number generator without concern for its properties. This limits the 
modeler’s ability to use the identical series of random numbers for alternative treat-
ment strategies or among comparators. Synchronization of model results between 
treatment arms within a model run is difﬁcult unless separate random streams are 
used for each source of variation. Synchronization of random number streams requires 
maintaining arrays of starting and current random number seeds. If each source of 
variation (e.g., times or probabilities of death and major events) has its own stream 
then the simulation of identical patients in all treatment arms is possible. By resetting 
the seed for each arm, the model results are impacted only by differences in model 
input point estimates (for ﬁrst-order analyses) or differences in the speciﬁed distribu-
tions of sampled model inputs (for second-order analyses). The impact of random 
number sampling is thus maximally correlated between treatments, and the differences 
in the occurrences of events common to both simulations, e.g., natural death, are not 
artiﬁcially inﬂated due to random sampling. Given a sufﬁcient number of replications, 
stochastic models usually produce stable results. This is because any further increase 
in the number of modeled replications will have minimal impact on the average-based 
model results. If the modeled result is the ratio of differences, such as an incremental 
cost effectiveness ratio (ICER), small differences in the denominator often drive the 
estimate, requiring a large number of replications. The allocation of common events, 
particularly natural death, to designated random streams minimizes the impact of 
random sampling on the model results. The number of model replications (and thus 
execution time) needed to produce stable ICERs may be reduced by as much as 90%.
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OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC 
and the allocation of $1.1Billion for comparative effectiveness research by the United 
States, are strong indicators of trends in pricing and reimbursement that are likely to 
be observed in the future. To gain an additional insight into these trends, we analyzed 
the cost effectiveness studies for the top ten highest selling drugs (∼$80–95B worldwide 
sales). METHODS: The Top 10 drugs were selected based on their worldwide sales. 
For this analysis, we segmented these drugs into categories as primary care, specialty, 
small molecules, biologics, therapy areas and availability of generic alternatives. We 
analyzed the cost effectiveness studies that were published in peer-reviewed journals. 
Search was conducted using generic names of the drugs and the phrase “cost effective-
ness” in abstract of the published study. RESULTS: During 2003–2008, the number 
of published studies on “cost effectiveness” have increased by more than 30%. Almost 
half of the published studies belong to—Remicade, Plavix and Enbrel. There is a large 
